Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

Go back to Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Merck & Co. (NYSE: MRK) Delayed: 148.78 +1.91 (1.30%)
Previous Close $146.87    52 Week High $65.46 
Open $146.79    52 Week Low $47.97 
Day High $149.19    P/E 101.21 
Day Low $145.60    EPS $1.47 
Volume 1,512,817